Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06227377 · ClinicalTrials.gov registry record · Phase 1
QTX3034 in Patients With KRAS G12D Mutation
A Phase 1 study of Solid Tumors, sponsored by Quanta Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 14
- Study locations
NCT06227377: Recruiting Phase 1 study of Solid Tumors, sponsored by Quanta Therapeutics.
NCT06227377 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Quanta Therapeutics. The registered enrollment target is 250 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (12% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06227377, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Quanta Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 14
- Study locations
Study Summary
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Primary Outcome
DLTs will be defined as the occurrence of any of the toxicities as described in the protocol
Conditions Studied
Interventions
- COMBINATION_PRODUCT Cetuximab
- DRUG QTX3034
Study Locations (14)
Florida
- Florida Cancer Specialists - Sarasota
- Moffitt Cancer Center - Tampa
New York
- NYU Langone Health - New York
- Montefiore Medical Center - The Bronx
Texas
- MD Anderson - Houston
- START San Antonio, LLC - San Antonio
California
- UCLA Hematology/Oncology - Los Angeles
Colorado
- Sarah Cannon Research Institute (SCRI) - Denver
Connecticut
- Yale Cancer Center - New Haven
North Carolina
- Duke University - Durham
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 1 |
What NCT06227377 shows while recruiting
NCT06227377 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT06227377 lists 14 locations in 11 states (Florida, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT06227377 about?
NCT06227377 is a clinical study titled "QTX3034 in Patients With KRAS G12D Mutation". Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
What is the current status of trial NCT06227377?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-02-05. Estimated completion is 2027-04-01.
What conditions does trial NCT06227377 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06227377?
The interventions under investigation include: Cetuximab (COMBINATION_PRODUCT), QTX3034 (DRUG).
Who is sponsoring clinical trial NCT06227377?
This trial is sponsored by Quanta Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06227377 being conducted?
This trial has 14 study locations across California, Colorado, Connecticut, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06227377's enrollment target sits among peer trials
250 25th of 125 higher than 100 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI